AKR1C1 interacts with STAT3 to increase intracellular glutathione and confers resistance to oxaliplatin in colorectal cancer
Oxaliplatin (OXA), a platinum-based chemotherapeutic agent, remains a mainstay in first-line treatments for advanced colorectal cancer (CRC). However, the eventual development of OXA resistance represents a significant clinical challenge. In the present study, we demonstrate that the aldo-keto reduc...
Saved in:
| Main Authors: | Zhiwen Fu, Tingting Wu, Chen Gao, Lulu Wang, Yu Zhang, Chen Shi |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | Acta Pharmaceutica Sinica B |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2211383524003502 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
AKR1B1 Expression in the Colorectal Tumor Microenvironment Contributes Towards Its Prognostic Significance
by: Seçil Demirkol Canlı, et al.
Published: (2025-05-01) -
In Vitro Analysis of AKR1D1 Interactions with Clopidogrel: Effects on Enzyme Activity and Gene Expression
by: Shutevska K, et al.
Published: (2025-03-01) -
Cloning, expression, and purification of recombinant AKR1D1 for therapeutic applications
by: Shutevska Kristina, et al.
Published: (2025-03-01) -
DIRAS1 Drives Oxaliplatin Resistance in Colorectal Cancer via PHB1-Mediated Mitochondrial Homeostasis
by: Min Long, et al.
Published: (2025-07-01) -
Analysis of the AKR1D1*36 (rs1872930) genetic variant in the Kosovo population: allele frequency and genotype distribution
by: Nora Elshani, et al.
Published: (2025-06-01)